Inhibition of Acinetobacter-Derived Cephalosporinase: Exploring the

Subscriber access provided by READING UNIV

Article

Inhibition of Acinetobacter-Derived Cephalosporinase (ADC): Exploring the Carboxylate Recognition Site Using Novel #-Lactamase Inhibitors Emilia Caselli, CHIARA ROMAGNOLI, Rachel A. Powers, Magdalena A. Taracila, Alexandra A Bouza, Hollister C Swanson, Kali A Smolen, Francesco Fini, Bradley J. Wallar, Robert A. Bonomo, and Fabio Prati ACS Infect. Dis., Just Accepted Manuscript • DOI: 10.1021/acsinfecdis.7b00153 • Publication Date (Web): 16 Nov 2017 Downloaded from http://pubs.acs.org on November 17, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

ACS Infectious Diseases is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Infectious Diseases

Inhibition of Acinetobacter-Derived Cephalosporinase (ADC): Exploring the Carboxylate Recognition Site Using Novel β-Lactamase Inhibitors Emilia Caselli†, Chiara Romagnoli†, Rachel A. Powers#, Magdalena A. Taracila‡, Alexandra A. Bouza#, Hollister C. Swanson#, Kali A. Smolen#, Francesco Fini†, Bradley J. Wallar#, Robert A. Bonomo∞,‡* and Fabio Prati,†* †

University of Modena and Reggio Emilia, Department of Life Sciences, via Campi 101, 41125, Modena, Italy #

Department of Chemistry, 1 Campus Drive, Grand Valley State University, Allendale, MI, 49401

∞

Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, 10701 East Blvd, Cleveland, OH, 44106

‡

Case Western Reserve University, Departments of Medicine, Pharmacology, Biochemistry and Molecular Biology and Microbiology, 10900 Euclid Avenue, Cleveland, OH, 44106 *Corresponding authors e-mail: [email protected]; [email protected]

ACS Paragon Plus Environment

1


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 43

Boronic acids are attracting a lot of attention as β-lactamase inhibitors, and in particular compound S02030 (Ki = 44 nM) proved to be a good lead compound against ADC-7 (Acinetobacter Derived Cephalosporinase), one of the most significant resistance determinants in A. baumannii. The atomic structure of the ADC-7/S02030 complex highlighted the importance of critical structural determinants for recognition of the boronic acids. Herein, to elucidate the role in recognition of the R2-carboxylate, which mimics the C3/C4 found in β-lactams, we designed, synthesized, and characterized six derivatives of S02030 (3a). Out of the six compounds, the best inhibitors proved to be those with an explicit negative charge (compounds 3a-c and 3h,j, Ki = 44-115 nM), which is in contrast to the derivatives where the negative charge is omitted, such as the amide derivative 3d (Ki = 224 nM) and the hydroxyamide derivative 3e (Ki = 155 nM). To develop a structural characterization of inhibitor binding in the active site, the X-ray crystal structures of ADC-7 in a complex with compounds 3c, SM23, and EC04 were determined. All three compounds share the same structural features as in S02030, but only differ in the carboxy-R2 side chain, thereby providing the opportunity of exploring the distinct binding mode of the negatively charged R2 side chain. This cephalosporinase demonstrates a high degree of versatility in recognition, employing different residues to directly interact with the carboxylate, thus suggesting the existence of a “carboxylate binding region” rather than binding site in ADC enzymes. Furthermore, this class of compounds was tested against resistant clinical strains of A. baumannii and are effective at inhibiting bacterial growth in conjunction with a βlactam antibiotic.

Keywords: β-lactamase, Boronic acid, Structure Activity Relationship, click chemistry, carboxylate, structure activity relationship (SAR) study, enzyme plasticity, Acinetobacter


2

Page 3 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Bacterial production of β-lactamases represents the most clinically challenging mechanism of resistance to β-lactam antibiotics in Gram-negative bacteria. Amongst these multidrug resistant bacteria, Acinetobacter baumannii is one of the greatest clinical threats due to its acquisition of numerous genetic determinants conferring resistance to all antibiotics.1 A. baumannii harbors multiple antibiotic resistance determinants, such as class C, D and B βlactamases, multidrug resistance efflux pumps, and a modified outer membrane that decreases permeability to antimicrobials. Furthermore, A. baumannii possesses the ability to acquire new resistance determinants by genetic exchange, natural transformation and outer membrane vesicles. Preserving and restoring the efficacy of β-lactam antibiotics, which are still the major class of drugs for the treatment of bacterial infections, is of critical importance as a strategy to overcome and circumvent resistance mechanisms against this challenging pathogen. The Acinetobacter-derived cephalosporinases (ADCs) are chromosomally-encoded class C β-lactamases found in A. baumannii and other Acinetobacter spp. and are responsible for resistance to penicillins, cephalosporins, and β-lactam/β-lactamase inhibitor combinations. Since clavulanic acid, sulbactam and tazobactam, the commercially available β-lactamase inhibitors bearing a β-lactam ring as their core structure, are not effective against ADC,2 the urgency of discovering new active inhibitors is pressing. The bridged diazabicyclo [3.2.1]-octanone avibactam entered the market in combination with ceftazidime and demonstrated potent inhibitory activity against most Enterobacteriaceae that produce class A and class C βlactamases, with some inhibitory capabilities against organisms producing class D enzymes. Notably, this combination is not targeted for A. baumannii3 and other solutions are urgently needed to treat infections caused by A. baumannii.


3


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 4 of 43

A class of non-β-lactam β-lactamase inhibitors that is recently attracting considerable attention for their activity and pharmacological profile are boronic acid transition-state inhibitors (BATSIs).4-7 Mechanistically, the electrophilic boron reacts with the nucleophilic catalytic serine leading to the formation of a tetrahedral adduct that mimics the high-energy intermediate of the deacylation reaction with β-lactams (Scheme 1). Previous studies showed that the insertion of different chemical groups on the carbon bearing the boronic moiety results in specific interactions with different β-lactamase enzymes, allowing for a gain in inhibitory function and selectivity tuned for a specific class of β-lactamases. Boronic acids have been widely used for inhibition of class C β-lactamases, such as AmpC, and recently they have been studied primarily for inhibition of the cephalosporinase of Acinetobacter spp. (ADC).8 Of the reported BATSIs, S02030 (compound 3a) is comprised with a set of features that makes it a promising lead compound against ADC, both for its structure and activity (Ki = 44 nM), as well as its efficient synthetic pathway.7 The chemical structure of S02030 was specifically designed to mimic the structure of the natural substrate cephalothin in the deacylation high energy intermediate with the β-lactamase (Figure 1). The structural features important for enzyme recognition and inhibition are depicted in Figure 1: an R1 amide side chain bearing a 2-thienylmethyl group, an oxyanion group represented by one boronic hydroxyl, and a R2 cyclic side chain bearing a carboxylate meant to mimic the C3/C4 carboxylate found in β-lactams. All these groups are spatially oriented as in the natural substrate, in order to gain the proper interactions with the enzyme.


4

Page 5 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


R1 amide side chain R2 side chain H N

S

O O

a.

R1 amide side chain S

S O-

N O OH O-Ser-BL

carboxylate

oxyanion hole

H N

R2 side chain

N

N

N O B OH OHO O-Ser-BL O

oxyanion hole

carboxylate

b.

Scheme 1. a. cephalothin-β-lactamase (BL) deacylation high energy intermediate. b. S02030 in complex with a serine β-lactamase. The crystal structure of ADC-7 in complex with S02030 demonstrated that the inhibitor is interacting with highly conserved residues in the catalytic pocket.7 In particular, the R1 amide side chain is positioned in a region analogous to where β-lactam substrates bind in other class C β-lactamases, interacting with highly conserved Asn152 and Gln120. Also, one hydroxyl group of the boronic acid is positioned in the oxyanion hole and made hydrogen bonds with the main chain nitrogens of Ser64 and Ser315 as well as the main chain carbonyl oxygen of Ser315. Interestingly, the position and role of the R2 side chain, and specifically the carboxylate, is not similar to other class C structures. In general, the C3/C4 carboxylate recognition site in class C enzymes is reported to be comprised of Asn346 and Arg349 (AmpC numbering), but while these residues were conserved in ADC-7 (Asn343 and Arg346), the carboxylate of S02030 interacted with Arg340, a residue that distinguishes ADC-7 from other AmpCs. In class A β-lactamases, the carboxylate binding pocket and the role of the carboxylate itself is well established;9-11 in class C β-lactamases, we confirmed that neither the residues involved in recognition nor the role of the carboxylate are sufficiently known.


5


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 6 of 43

To elucidate the residues that take part in carboxylate recognition in ADC-7 and its importance for β-lactamase inhibition, we report the synthesis and characterization of six S02030 derivatives (3b-e, 3h, 3j) specifically designed to insert unique modifications localized on the R2 triazole substituent. Specific localized modifications were easily introduced using the flexible and efficient synthesis previously described which relies on “click chemistry”, specifically, the well-known copper-catalyzed azide-alkyne cycloaddition (CuAAC).12 According to this procedure, the substituted triazole moiety is formed by reaction of the chiral boronic scaffold 1, bearing both the R1 thienylacetamido side chain and an azido group, with the proper monosubstituted alkyne (Scheme 2). These alkynes are specifically chosen to introduce rational variation of the carboxylate. Scheme 2.

3a = -COOH H N

S O

1

O

N3 B

O

1)

R Cu(I)

2) deprotection

S

H N

N

B O HO OH 3a-j

N N R

3b = -CH2COOH

3e = -CONHOH 3h = N N

3c = -m-C6H5COOH 3d = -CONH2

3j =

NH N H N N N N

All synthesized BATSIs were tested against ADC-7 and confirmed to be potent inhibitors. Since the best inhibition values were obtained for compounds with an explicit negative charge, two additional boronic acids (SM2313 and EC01414) were tested and confirmed to be amongst the best inhibitors. To elucidate the specific residues that interact with the carboxylate, we determined the crystal structures of ADC-7 in complex with the boronic acids 3c, SM23 and EC04. Comparison of these structures reveals critical differences in binding of the carboxylate. The variability in the active site interactions with the R2-carboxylate suggests that


6

Page 7 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


class C β-lactamases display a high degree of plasticity and flexibility for recognition, pointing to the existence of a carboxylate “binding region” rather than a “binding site” in ADC-7. The synergistic effect of these inhibitors paired with β-lactams to reverse antibiotic resistance in whole cell assays against Escherichia coli and Acinetobacter baumannii strains expressing ADC7 was also explored. RESULTS Design. In previous studies, we demonstrated that boronic acids of general structure 3 were excellent inhibitors against class C β-lactamases,12 and in particular 3a was a 44 nM inhibitor of ADC-7 cephalosporinase.7 In this study, our goal was to elucidate the role of the carboxylate in enzyme-inhibitor recognition.

To achieve this end, we introduced specific

modifications near this R2-carboxylate group. Specifically, the carboxylate of 3a is elongated with addition of a methylene bridge (3b), inserted on the meta-position of a phenyl ring (3c), modified to an amide group (3d) and to an hydroxamate (3e) and finally replaced by the bioisostere tetrazole, either directly bonded to the triazole (3h) or as a meta-substituent on the phenyl ring (3j). Compounds 3b, 3c, 3h and 3j are explicitly designed to introduce distance modifications between the negative charge of the carboxylate and the electrophilic boron atom, whereas the amide 3d and the hydroxamate 3e change the protonation profile of the substituent while still maintaining heteroatoms able to form hydrogen bonds with the enzyme residues. Synthesis of α-2-Thienylacetamido-β β -Triazolylethaneboronic Acids. The synthesis of compounds 3b-j is depicted in Scheme 3.


7


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

H N

S O

O

N3 B

O

1

R 72-99%

H N

S O

O

2b R= -CH2COOH 2c R= -C6H5COOH 2d R= -CONH2

N B

O

Page 8 of 43

N

Deprotection

N

81-96% R

2f R= -CN 2h R=

N N

NH N

H N

S

N

O B HO OH

N N R

3a R= -COOH

3e R= -CONHOH

3b R= -CH2COOH

3h R= N

3c R= -C6H5COOH 2g R= -C6H5CN 3d R= -CONH2

2e R= -CONHOH 2j R=

N

NH N H N N N N

3j R=

H N N N N

Scheme 3. General Synthesis of α-2-Thienylacetamido-β-Triazolylethaneboronic Acids 3. (+)-Pinanediol (1R)-2-Azido-1-[(2-thienylacetyl)amino]-ethaneboronate 1 was obtained as previously described.12 Compound 1 was then reacted with six terminal alkynes in the copper catalyzed Azide-Alkyne Cycloaddition (CuAAC). Amongst the six chosen alkynes, 3-butynoic acid (R= –CH2COOH, for the synthesis of compound 2b) and 3-carboxyphenylacetylene (R= – m-C6H5COOH, for compound 2c) are commercially available, whereas the other four alkynes, propiolamide15 (R= –CONH2, for compound 2d), N-hydroxypropiolamide (R= –CONHOH, for compound 2e),16 propiolonitrile (2f)17 and 3-ethynylbenzonitrile (2g)18 were prepared following established procedures. As already described for compound 3a, formation of the triazole was conducted in very mild conditions, in water/tert-butyl alcohol as solvent, generating the Cu(I) catalyst in situ from CuSO4 in the presence of an excess of ascorbate as reducing agent (5% catalyst, 20% ascorbate) and at 60°C for approximately two hours. The expected triazole 2b-g were recovered in goodexcellent yields (72-99%) by extraction with ethyl acetate and crystallization of the crude (Scheme 3). The formation of the triazole was confirmed by the presence in the 1HNMR spectra


8

Page 9 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


of a singlet downfield at 8.0-8.7 ppm which correlates (HSQC experiments) with a signal at 118131 ppm of the 13C NMR spectra, as expected for a triazolic CH. Moreover, the 1,4 substitution was confirmed by the long-range correlation (HMBC experiment). Triazoles 2h-j were obtained by treatment of the cyano precursors with tetrabutylammonium fluoride trihydrate in trimethylsililazide as solvent. Final deprotection of (+)-pinanediolesters was accomplished by transesterification with phenylboronic acid (isobutylboronic acid in case of 3h and 3j) in a biphasic system of acetonitrile/n-hexane, to afford the final BATSIs 3b-e, 3h and 3j in 81-96% yield.

Inhibition Kinetics. The binding affinities for each of the BATSIs with ADC-7 were determined using competition kinetics. Utilizing nitrocefin, NCF, as a colorimetric substrate of ADC-7, boronic acids 3a-e, 3h and 3j were tested as inhibitors of ADC-7 β-lactamase. Additionally, three reference BATSIs were tested: compound s08127,12 which lacks the substituent on the triazole ring, compound EC04,14 which replaces the triazole with a phenyl group, and compound SM2313 where the phenyl aromatic moiety is directly connected to the boron bearing carbon atom. The Ki values were calculated for all ten BATSIs and reported in Table 1.


9


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 10 of 43

Table 1: Ki values of Compound 3 derivatives with ADC-7

Cmp

Structure

R

Ki [nM]

3a

COOH

44 ± 2

3b

CH2-COOH

115 ± 2

COOH

3c

CONH2

3d 3e

H N

S

HN OH N

O B HO OH

3h

N N

224 ± 2 155 ± 3

O

R N N H

3j

N N

N N N NH

76 ± 2 99 ± 2

658 ± 6

s08127

EC04

46 ± 3

S

H N O B HO OH

–

53±4

–

22±2

COOH

SM23

S

H N

COOH

O B HO OH

All BATSIs were shown to be very active ADC-7 inhibitors with Ki values in the nanomolar range. We observed that affinity is diminished when the inhibitor lacks the carboxylate group, such as for s08127 (Ki = 658 nM), and is less significant when the negative charge is not present, as for the amide and hydroxyamate derivatives 3d and 3e (Ki = 224 and 155 nM respectively). Compound 3a proved to be a potent inhibitor of ADC-7, with a Ki of 44


10

Page 11 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


nM. The boronic acid 3b, which exhibits an additional methylene linker between the carboxylate and the triazole, demonstrates less activity by three-fold (Ki = 115 nM), whereas 3c (Ki = 46 nM), bearing a phenyl linker, exhibits an equivalent activity to 3a. Inhibition is diminished when the carboxylate negative charge is replaced by an amide derivative 3d (Ki = 224 nM) or a hydroxyamide group 3e (Ki = 155 nM). We synthesized two additional boronates where the negatively charged carboxylate is substituted with its bioisostere tetrazole, a group with a similar pKa value, but a wider distribution of the negative charge. Indeed, the presence of a net negative charge as for compound 3h (Ki = 76 nM) and for the phenyltetrazole 3j (Ki = 99 nM) improves activity with respect to inhibitors lacking this negative charge. The binding affinity of all the other BATSIs spans from 22 nM (for SM23) to 115 nM (3b), thus confirming the importance of a negative charge in the R2 side chain for recognition, and simultaneously suggesting the presence of a “binding region” for this carboxylate rather than of a “binding site” (Table 1). X-ray Crystal Structures of ADC-7 in Complex with SM23, EC04 and 3c BATSIs. To further define the role of the carboxylate group for ADC-7 inhibition, the complexes of ADC7 with SM23, EC04 and 3c were determined by X-ray crystallography to resolutions ranging from 1.88-1.95 Å (Table 2, Figure 1). Each of the three inhibitors bears an unmasked carboxylate at varying distances from the electrophilic boron. Complexes were obtained by soaking the inhibitors into pre-formed ADC-7 crystals. The complexes crystallized in the same space group (P21) with similar cell parameters. Inspection of the initial Fo – Fc maps countered at 3σ showed unambiguous electron density for the inhibitors bound in the active sites of each structure. The density was contiguous with the Oγ atom of Ser64, suggesting that the inhibitors were covalently


11


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 12 of 43

attached to the catalytic serine residue, Ser64. Refinement of the inhibitors modeled into the density revealed a tetrahedral geometry around the boron atom as expected. For compounds EC04 and 3c, the position of the carboxylate was unambiguous, but electron density for the SM23 carboxylate suggests two distinct conformations for the negative charge.


12

Page 13 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Table 2. Crystallographic summary for the ADC-7/BATSI complexes. ADC-7/3c

ADC-7/EC04

ADC-7/SM23

Cell constants (Å; °)

a=89.01 b=81.30 c=106.44; β=112.70

a=89.53 b=81.30 c=106.69; β=112.89

a=88.71 b=81.65 c=106.42; β=112.84

Space group

P21

P21

P21

Resolution (Å)

1.88 (1.89-1.88)a

1.88 (1.89-1.88)a

1.95 (1.96-1.95)a

Unique reflections

113,977

113,662

101,377

Total observations

475,114

477,304

418,250

Rmerge (%)

6.7 (62.4)

5.9 (65.3)

9.0 (70.6)

Completeness (%)b

99.8 (99.8)

99.0 (98.1)

99.6 (99.6)

13.5 (2.2)

15.7 (2.2)

11.9 (2.3)

0.998 (0.732)

0.996 (0.734)

0.997 (0.719)

50.00-1.88

98.28-1.88

98.07-1.95

1,424

1,423

1,426

589

516

628

0.018

0.018

0.018

R-factor (%)

1.896

1.865

1.915

Rfree (%)c

20.2

20.1

18.7

Average B-factor, protein atoms (Å2)

25.6

25.5

24.6

Average B-factor, water molecules (Å2)

37.0

40.5

37.0

36.7

38.4

37.1

Resolution range for refinement (Å) Number of protein residues Number of water molecules RMSD bond lengths (Å) RMSD bond angles (°)

Average B-factor, inhibitor atoms (Å2)

a. Values in parentheses are for the highest resolution shell. b. Fraction of theoretically possible reflections observed. c. Rfree was calculated with 5% of reflections set aside randomly.


13


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 14 of 43

SM23

EC04

3c


14

Page 15 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 1: Stereoview of the SM23, EC04, 3c BATSIs bound to the catalytic residue, Ser64 of ADC-7. Fo-Fc omit maps are contoured at 2.5 σ. Atom coloring is as follows: oxygen atoms are red, nitrogens blue, sulfurs yellow, borons pink, carbon atoms of SM23 are white, for EC04 carbons are cyan, and for 3c carbons are green. This figure was generated with PyMOL [Schrodinger].

The structures of the three BATSIs bound in the active site reconfirm the features essential for enzyme-inhibitor recognition of both the R1 and R2 groups (Figure 2), initially described in the ADC-7/S02030 complex. Briefly, the inhibitor R1 side chain is bound in the highly-conserved amide binding site, where the amide oxygen hydrogen bonds with the side chain nitrogen atoms of Gln120 and Asn152 and the main chain amide nitrogen and oxygen atoms of Ser315, reminiscent of β-lactamase recognition of the R1 amide group of β-lactam substrates. The inhibitor O1 hydroxyl groups are positioned in the oxyanion hole, hydrogen bonding with the main chain nitrogens of Ser315 and Ser64 and also with the main chain oxygen of Ser315. The inhibitor O2 hydroxyl groups make hydrogen bonds with the side chain hydroxyl of Tyr150, as well as water molecule observed in most class C β-lactamase complexes. The distal thiophene ring common to the inhibitors is positioned near the lip of the active site in all three structures, extending over Tyr222 (Tyr221 in AmpC numbering). The thiophene ring of EC04 and SM23 is observed to adopt two distinct conformations that exhibit an approximate 180° rotation of the thiophene ring; in 3c, only one conformer is observed. The R2 side chains display more variability in their binding modes than the R1 groups. The carboxylate-bearing R2 side chain is structurally different in the three BATSIs, and the


15


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 16 of 43

negatively charged group is observed to bind in two regions of the ADC-7 active site. The chemical structures of SM23 and EC04 are relatively similar, differing from each other by a single carbon spacer between the boron-bearing carbon atom and the aromatic ring of EC04. The carboxylate groups are bound in essentially the same region, a site comprised of residues Ser315, Arg340, and Asn343. In the EC04 complex, the inhibitor carboxylate hydrogen bonds with the amide nitrogen of Asn343 (3.2Å) and interacts with Arg340 via a water-mediated bridge (Wat412). This water molecule is not observed in the ADC-7/SM23 complex, where the carboxylate of SM23 occupies that space and adopts two conformations. In the first conformation, the carboxylate hydrogen bonds directly to Arg340 (2.6Å) and Asn343Nδ2 (3.2Å) and in the second, with the side chain hydroxyl of Ser315 (3.0Å) and a water molecule (Wat227; 2.9Å). Compound 3c varies more from the chemical structures of SM23 and EC04 in that 3c is more extended due to the addition of a triazole linker between the boron and the benzoic acid functionality. This linker allows the R2 group of 3c to extend over the R1 group and places the carboxylate group toward an area near the edge of the active site. In this location, the carboxylate is observed in a hydrogen bond with the side chain of Ser317 and near the bulk solvent. Additionally, in this extended conformation, the aryl ring of 3c is positioned near Arg340 (Cζcentroid of aryl ring = 4.0 Å), making a potential cation-π interaction with this conserved residue in the ADC enzymes.


16

Page 17 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


SM23

EC04

3c

Figure 2: SM23 (white), EC04 (cyan), 3c (lime green). Stereoview of the ADC-7 active site in complex with three, R2-containing BATSIs. Hydrogen bonds observed are shown as yellow, dashed lines. Cation-π interactions are shown as magenta dashed lines. Water molecules are shown as red spheres. Oxygens are colored red, nitrogens blue, boron pink and sulfur yellow. The carbon atoms of the active site residues and BATSIs are colored by the various inhibitors in complex with ADC-7.


17


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 18 of 43

Antimicrobial Activity. Disk susceptibility assays (DSAs) were performed using an E.coli carrying the phagemid pBC SK expressing blaADC-7 construct and in an A. baumannii clinical strain. In both cases, significant inhibition of ADC-7 β-lactamase by the BATSIs is observed at a concentration of 10µg/mL when partnered with the β-lactam ceftazidime (CAZ) for the E. coli strain, and sulbactam (SULB) for the A. baumannii isolate tested (Table 3). The DSA zone disk increased from 12 mm for CAZ alone to up to 26 mm for the best inhibitor 3a. The results were very encouraging as the boronate compounds show cell penetration against clinical isolates of A. baumannii when paired with sulbactam with the best ones, 3a and 3c increasing the disk size from 6 mm to 16 and 15 mm, respectively. The broth MICs results show that the addition of the BAI decreases the CAZ MIC from 32µg/ml to 1-2µg/ml for 3a, SM23, 3b, 3c, 3e, 3h, EC04. The results from DSA and broth MIC reveal that most of the compounds perform similarly under the agar or liquid condition. The slight difference is for S08127, which perform relatively better in liquid that in agar media, which can be attributed to lower diffusion properties in agar. The highest MIC (8 µg/ml) for compound 3j (despite a very good affinity Ki=99nM) can be due to cell penetration.


18

Page 19 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Table 3. MIC were determined using the broth microdilution method with 10µg/ml compound, and varying amounts of CAZ (from 0 to 128µg/ml) The DSAs were performed against E. coli DH10B using ceftazidime as the BATSI antibiotic partner, and sulbactam for the AB0057 clinical strain (10µg BAI and 10 µg antibiotic partner). E. coli carrying blaADC-7 encoded in pBC SK (-) Cmpd.

AB0057 A. baumannii spp. clinical strain

none

MIC broth dilution [µg/ml] 32

Disk assay [mm] CAZ 12 mm

Disk assay [mm] SUL 6 mm

3a

1

26

16

3b

2

18

10

3c

2

24

15

3d

4

18

10

3e

2

16

8

3h

2

23

10

3j

8

15

6

s08127

4

12

6

EC04

2

21

11

SM23

1

25

12

DISCUSSION AND CONCLUSIONS Although boronic acids are a class of compounds known since the 1980s to act as βlactamase inhibitors,19,20 a significant amount of effort is presently focused on the discovery of potent and selective boronic inhibitors to be administered together with a β-lactam. Currently, a boronic acid, RPX7009 (vaborbactam), is commercially available in combination with meropenem to treat carbapenem resistant Enterobacteriaceae infections.21 Unfortunately, this


19


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 20 of 43

combination displays only a little enhancement of meropenem activity when tested against carbapenem-resistant A. baumannii or P. aeruginosa.22 Thus far, several different classes of boronic acid inhibitors have been discovered. These compounds display different profiles of activity, both in terms of microbiological and enzymatic potency. In this study, we report our attempt to identify specific molecular determinants for the recognition of BATSIs by a representative class C β-lactamase expressed in A. baumannii, ADC7. We conducted a SAR study on the BATSI’s R2-carboxylate which is designed to mimic the C3/C4 carboxylate found in β-lactams, starting from the lead compound S02030 (compound 3a). The high degree of flexibility of the synthesis developed for this lead compound that bears a simple carboxylate and the triazole substituent, allows easy access of a focused small library of compounds bearing different substituents that aim either to: 1) distance the carboxylate from the electrophilic center, 2) substitute the carboxylate with the bioisostere tetrazole, or 3) replace the negative charge with an amide or a hydroxamide. The data reported herein suggest that ADC-7 β-lactamase recognizes a negative charge in this region, probably employing different residues in recognition. Indeed, compound s08127, which lacks the substituent on the triazole ring, shows a significantly less potent Ki of 658 nM, whereas the other two BATSIs bearing a m-carboxyphenyl (SM23, Ki = 22 nM) or a mcarboxybenzyl (EC04, Ki = 56 nM) side chain, restore a comparable activity to the β-triazole derivatives. To better understand the role of the carboxylate in this class of inhibitors, we determined crystallographic complexes of ADC-7 in a complex with three BATSIs that all have a carboxylate in the R2 side chain: SM23, EC04 and 3c. The carboxylate is positioned on a phenyl


20

Page 21 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


ring in both SM23 and EC04, with the only difference being that EC04 contains an additional methylene bridge between the aromatic moiety and the α-carbon. Compound 3c is structurally different, since it keeps the additional methylene linker, but replaces the phenyl with a triazole that bears a meta-carboxyphenyl substituent at position 4. The presence of two aromatic rings between the boronic group and the carboxylate not only alters the distance of the negative charge to the electrophilic center, but also adds hydrophobic character to the inhibitor. A superposition of the ADC-7 active site in complex with the three R2-containing BATSIs highlights that the R1 side chain of all three structures maintain a similar conformation and therefore the same interactions with active site residues. However, the R2-carboxylate is located in distinct binding regions (Figure 3).

Figure 3. Stereoview superposition of the ADC-7 active site in complex with the R2-containing BATSIs; 3c (green), EC04 (cyan), SM23 (white). In compounds SM23 and EC04, the carboxylate is pointing towards a binding region previously identified in the crystal structure of ADC-7 in complex with the lead compound S02030. This region is positively charged due to the presence of Arg340, which is either interacting directly with the carboxylate (SM23) or through a water molecule(EC04) making it


21


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 22 of 43

an attractive binding site for a negatively charged carboxylate group in ADC-7 and possibly other ADCs that contain this conserved residue. However, Arg340 is not ubiquitous among all class C β-lactamases. For example, the crystal structure of E. coli AmpC in complex with SM2313 shows a direct hydrogen bond between the inhibitor carboxylate and Asn289; a residue that is not conserved in related class C lactamases, such as E. cloacae P99, where this residue is a serine. Interestingly in ADC-7, this interaction is not present due to an Asp at the analogous position, as this negatively charged residue is flipped away from the inhibitor R2-carboxylate group. The presence of Arg340 seems crucial for inhibitor recognition in ADC-7: compound 3c has an extended R2 side chain due to the presence of two aromatic rings, therefore its carboxylate is placed in a different region of the enzyme, interacting with the side chain of Ser317, whereas Arg340 is in the position for a cation-π interaction with the inhibitor aryl ring. Together, these two interactions seem to contribute to reach the same level of inhibition as for compounds SM23 and EC04 (Figure 2 and Table 1). Cation-π interactions have been shown to contribute to protein-protein and protein-ligand interactions across a broad range of the biological realm23 and arginine residues have been proposed to play a role in the structural stability of numerous β-lactamases.24 The Arg340 residue therefore seems to attract a negative charge in this region, but also demonstrates a high degree of versatility in recognition. On the other hand, data previously obtained on compounds SM23 and EC04 against E. coli AmpC (Ki values of 1 nM)13, and Pseudomonas PDC-3 (Ki values of 4 and 220 nM, respectively)14, two class C enzymes lacking Arg340, point to the high plasticity of this class of enzymes. This plasticity allows the class C β-lactamases to take advantage of different functional groups that are not conserved with respect to position in primary sequence, but which can mediate the same role in recognition of inhibitors and possibly β-lactam substrates.


22

Page 23 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Microbiological data suggest the importance of the carboxylate, not only for recognition, but also for cell activity. Our data suggest that cell penetration is enhanced by compounds possessing a carboxylate functional group, followed by ones with hydroxamide functionality. These data also show that cell penetration correlates well with affinity. The only compound with good binding affinity but poor microbiological activity is compound 3j. For this compound, the R2 chain comprises three aromatic rings with the triazole and the phenyl ring that are likely to conserve the binding interaction observed with 3c (cation-π) with Arg340, and the third tetrazole ring placing the negative charge toward an area near the distal site (Ser317-Asn213) and the bulk solvent. However, the dispersion of the negative charge on an aromatic moiety is not beneficial for the cell penetration. In conclusion, this work describes a SAR study on the role of the carboxylate R2 group of a previously identified β-lactamase BATSI, compound S02030 (3a), which proved to be an excellent inhibitor of ADC-7. The synthetic approach to 3a and its derivatives, which relies on the robust CuAAC click reaction, gives easy access to specifically designed modifications of the carboxylate position. This study demonstrates that insertion of a negative charge in this position improves binding affinity and cell penetration; however, due to the high degree of plasticity of ADC, a wider choice of R2 negatively charged groups could be explored in future inhibitor design. METHODS Protein Preparation and Purification A version of ADC-7 beginning at amino acid D24 and ending at K383 was cloned into a pET28a(+) plasmid (no His-tag), expressed in the competent E. coli strain, BL21 (DE3), and affinity purified by a m-aminophenyl boronic acid column as previously described.7 Using the


23


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 24 of 43

A280 with an extinction coefficient of 46,300 M-1, the concentration of ADC-7 was determined. The extinction coefficient was calculated for the expressed residues in the ADC-7 construct by the ProtParam tool on the ExPASy bioinformatics portal. ADC-7 X-ray structure determination The ADC-7 crystals were grown by hanging drop vapor diffusion at room temperature. The crystallization conditions consisted of 3 mg/mL ADC-7 in 25% w/v polyethylene glycol 1500, 0.1 M succinate/phosphate/glycine buffer at pH 5.0 (SPG buffer, Molecular Dimensions). The crystals were harvested from the drop using a nylon loop and soaked in crystallization buffer containing 1 mM BATSI for 5-10 min and subsequently cryocooled in liquid nitrogen. Data were measured for each ADC-7/BATSI complex from an individual crystal at LS-CAT sector (21-1DG Beamline) at the Advanced Photon Source at Argonne National Laboratory (Argonne, IL). The images were indexed, integrated and scaled with XDS.25 Molecular replacement was carried out with Phaser26 using the ADC-7 apo structure (PDB 4U0T).7 Refmac5 in the CCP4 program suite was utilized to perform refinements.27,28 Repeated rounds of model building optimization were completed using Coot.29 The coordinates and structure parameters for the ADC-7/BATSI complexes are stored with the Protein Data Bank as 5W12 (EC04), 5W13 (SM23), and 5W14 (3c). Steady State Kinetics Using an Agilent 8453 diode array spectrophotometer at room temperature, competition kinetics were conducted in 10 mM phosphate-buffered saline, pH 7.4. The β-lactam substrate and colorimetric indicator, nitrocefin (NCF, ∆ε482 = 17400 M-1 cm-1), was utilized. In each assay, the measurements were taken after a 5 minutes pre-incubation of enzyme with BATSI. The average velocities (v0) were then fitted to equation 1,


24

Page 25 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


‫ݒ‬଴ = ‫ݒ‬௨ −

௩ೠ [ூ]

(1)

௄೔(೚್ೞ೐ೝೡ೐೏) ା[ூ]

where vu represents the uninhibited turnover of NCF, Ki(observed) is the concentration of inhibitor that results in a 50 percent reduction of vu, and [I] is the concentration of inhibitor in the experiment. Ki values were also corrected for NCF affinity (Km = 21.2 µM) according to equation 2,

‫ܭ‬௜(௖௢௥௥௘௖௧௘ௗ) =

௄೔(೚್ೞ೐ೝೡ೐೏) ଵା

[ಿ಴ಷ] ಼೘ಿ಴ಷ

.

(2)

Disk Susceptibility Assays (DSAs) and Minimum Inhibitory Concentrations (MICs) DSAs and MICs broth microdilutions were performed as previously described7 and according to Clinical and Laboratory Standards Institute (CLSI) guidelines and methods30. Bacterial cultures were grown overnight in Mueller-Hinton (MH) broth supplemented with 20 µg/mL of chloramphenicol to ensure maintenance of the β-lactamase plasmid in pBC SK (−) containing Escherichia coli DH10B strains. Liquid cultures were then diluted using MH broth to a McFarland Standard (OD600 = 0.224). For DSA assay, bacteria were plated on MH agar and a disk containing 10 µg of boronic acid compounds and 10 µg of ceftazidime or sulbactam were added. After an overnight incubation at 37 °C, zone sizes were measured and reported. For the MIC broth microdilution determinations, 200µl MH broth containing 10µg/ml BAI and increasing concentration of CAZ (from 0 to 128µg/ml) was inoculated with the overnight culture. After overnight incubation, MICs were determined. Synthesis All reactions were performed under argon using oven-dried glassware and dry solvents. Dry tetrahydrofuran (THF) and diethyl ether were obtained by standard methods and freshly distilled


25


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 26 of 43

under argon from sodium benzophenone ketyl prior to use. The –100 °C bath was prepared by addition of liquid nitrogen to a pre-cooled (–78 °C) mixture of ethanol/methanol (1:1). Preloaded (0.25 mm) glass supported silica gel plates (Kieselgel 60, Merck) were used for TLC analysis, and compounds were visualized by exposure to UV light and by dipping the plates in 1 % Ce(SO4)·4H2O, 2.5% (NH4)6Mo7O24·4H2O in 10% sulfuric acid followed by heating on a hot plate. Chromatographic purification of the compounds was performed on silica gel (particle size 0.05-0.20 mm). Melting points were measured in open capillary tubes on a Stuart SMP30 Melting Point apparatus and are uncorrected. Optical rotations were determined at +20 °C on a Perkin-Elmer 241 polarimeter and are expressed in 10-1 deg cm2 g-1. 1H and

13

C NMR spectra

were recorded on a Bruker Avance-400 MHz spectrometer. Chemical shifts (δ) are reported in ppm and were calibrated to the residual signals of the deuterated solvent.27,28 Multiplicity is given as s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad signal; coupling constants (J) are given in Hz. Two-dimensional NMR techniques (COSY, HMBC, HSQC) were used to aid in the assignment of signals in 1H and 13C spectra. Particularly, in the 13C spectra, the signal of the boron-bearing carbon atom tends to be broadened, often beyond the detection limit; however, its resonance was unambiguously determined by HSQC. Mass spectra were determined on an Agilent Technologies LC-MS (n) Ion Trap 6310A (ESI, 70 eV). High-resolution mass spectra were recorded on an Agilent Technologies 6520 Accurate-Mass Q-TOF LC/MS. The purity of all tested compounds was above 95%, determined by elemental analysis performed on a Carlo Erba elemental analyzer 1110; results from elemental analyses for the compounds were within 0.3% of the theoretical values. Combustion analysis and mass spectrometry of free boronic acids provided inaccurate results because of the formation of


26

Page 27 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


dehydration products.31 Nevertheless, these boronic acids could be converted into analytically pure pinanediol esters by exposure to an equimolar amount of pinanediol in anhydrous THF.

(+)-Pinanediol

(1R)-2-azido-1-(2-thienylacetylamino)-ethaneboronate

(1),

(1R)-2-[4-

carboxy-[1,2,3]triazol-1-yl]-1-(2-thienylacetylamino)ethaneboronic acid (3a) and (1R)-2-[4(3-carboxyphenyl)-[1,2,3]triazol-1-yl]-1-(2-thienylacetylamino)ethaneboronic acid (3c) were synthesized according to the literature.12 General Procedure for Cu/C-catalyzed “click” reaction: In a glass vial (+)-Pinanediol (1R)-2-azido-1-(2-thienylacetylamino)-ethaneboronate 1 (0.4 mmol) and the proper alkyne (0.4 mmol) were dissolved in tert-BuOH (3 mL) and CuSO4 (0.04 mmol), sodium ascorbate (0.08 mmol) and water (3 mL) were added. The vessel was sealed and temperature raised at 60 °C. The reaction was monitored through TLC until disappearance of the azidoboronate. After the proper reaction time, that spanned from 0.5 hour for more activated alkynes to 2 hours for less activated alkynes, the reaction mixture was partitioned between EtOAc (30 mL), H2O (12 mL) and saturated NaCl (7 mL). The aqueous phase was extracted with EtOAc (2 x 20 mL) and the combined organic phases were washed with saturated NaCl, dried over Na2SO4, and concentrated under vacuum to afford the crude product which was thereafter purified as described.

(+)-Pinanediol

(1R)-2-(4-carboxymethyl-[1,2,3]-triazol-1-yl)-1-(2-

thienylacetylamino)-ethaneboronate (2b). The reaction was terminated after 1 hour. The crude residue was triturated from diethylether to afford 2b as a white solid (117 mg, 80% yield), mp 180-182°C. [α]D – 94.5 (c 0.9, MeOH). 1H NMR (400 MHz, DMSO): δ 0.81 (3H, s, pinanyl


27


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 28 of 43

CH3), 1.22 (3H, s, pinanyl CH3), 1.24 (3H, s, pinanyl CH3), 1.36 (1H, d, J = 10.0, pinanyl Hendo), 1.64-2.33 (5H, m, pinanyl protons), 2.98-3.02 (1H, m, BCHCH2), 3.66 (2H, s, CH2COOH), 3.90 (2H, s, CH2CONH), 4.05 (1H, d, J = 6.7, CHOB), 4.22-4.39 (2H, m, BCHCH2), 6.95-6.99 (2H, m, Har), 7.42-7.44 (1H, m, Har), 8.00 (1H, s, CHtriazole), 9.75 (1H, s, CH2COOH).

13

C NMR (100 MHz, DMSO): δ 24.4, 26.7, 27.7, 29.6, 32.1, 37.0, 38.1, 43.1 (br,

CB), 52.4, 76.0, 83.0, 124.2 (CHtriazole), 126.2, 127.3, 127.4, 135.2, 140.6, 171.9, 175.4. MS (ESI, Ion Trap): 473 [M + H]+, MS/MS 473, m/z (%): 346 (50), 321 (100), 168 (8). Anal. Calcd for C22H29BN4O5S: C, 55,94; H, 6,19; N, 11,86; S, 6, 79. Found: C, 55.69; H, 6.21; N, 11.70; S, 6.93

(+)-Pinanediol

(1R)-2-(4-carboxamido-[1,2,3]triazol-1-yl)-1-(2-

thienylacetylamino)ethaneboronate (2d). Propiolamide was prepared from ethylpropiolate according to literature procedure.15 The reaction was terminated after 30 min. The crude residue was crystallized from EtOAc and n-hexane to afford 2d as a beige solid (162 mg, 89% yield), mp 144-146 °C. [α]D – 50.9 (c 0.9, MeOH). 1H NMR (400 MHz, MeOD): δ 0.91 (3H, s, pinanyl CH3), 1.33 (3H, s, pinanyl CH3), 1.38 (3H, s, pinanyl CH3), 1.43 (1H, d, J = 9.4, pinanyl Hendo), 1.80-2.40 (5H, m, pinanyl protons), 3.20 (1H, dd, J = 3.9, 10.6, BCHCH2), 3.98 (2H, s, CH2CONH), 4.22 (1H, d, J = 6.9, CHOB), 4.43 (1H, dd, J = 10.6, 14.5, BCHCH2), 4.60 (1H, dd, J = 4.0, 14.5, BCHCH2), 6.97-7.00 (2H, m, Har), 7.34 (1H, dd, J = 1.5, 5.0, Har), 8.45 (1H, s, CHtriazole). 13C NMR (100 MHz, MeOD): δ 23.2, 26.2, 26.4, 28.3, 31.0, 36.3, 37.7, 40.0, 44.4 (br, CB), 52.2, 52.3, 76.1, 83.2, 125.4, 126.7 (CHtriazole), 126.8, 127.3, 133.2, 142.3, 163.4, 177.8. MS (ESI, Ion Trap): 458 [M + H]+, MS/MS 458, m/z (%): 387 (3), 346 (22), 306 (100), 168 (4). Anal. Calcd for C21H28BN5O4S: C, 55.15; H, 6.17; N, 15.31, S, 7.01. Found: C, 54.88; H, 6.01; N, 15.25; S, 6.88.


28

Page 29 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(+)-Pinanediol

(1R)-2-(4-idroxycarbamoyl-[1,2,3]triazol-1-yl)-1-(2-

thienylacetylamino)ethaneboronate (2e). N-hydroxypropiolamide was prepared from propiolic acid according to literature procedure.16 The reaction was terminated after 30 min. The crude residue was crystallized from EtOAc and n-hexane to afford 2e as a beige solid (155 mg, 82% yield), mp 105°C (dec). [α]D – 64.3 (c 0.6, CHCl3). 1H NMR (400 MHz, MeOD): δ 0.90 (3H, s, pinanyl CH3), 1.31 (3H, s, pinanyl CH3), 1.38 (3H, s, pinanyl CH3), 1.43 (1H, d, J = 9.4, pinanyl Hendo), 1.79-2.40 (5H, m, pinanyl protons), 3.20 (1H, dd, J = 3.9, 10.3, BCHCH2), 3.98 (2H, s, CH2CONH), 4.22 (1H, d, J = 8.5, CHOB), 4.40-4.62 (2H, m, BCHCH2), 6.95-7.00 (2H, m, Har), 7.34 (1H, dd, J = 1.5, 5.0, Har), 8.44 (1H, s, CHtriazole).

13

C NMR (100 MHz, MeOD): δ 24.6,

27.6, 27.8, 29.7, 32.4, 37.7, 39.2, 41.4, 45.7 (br, CB), 53.6, 53.7, 77.5, 84.6, 126.8, 127.8 (CHtriazole), 128.1, 128.7, 134.6, 139.8, 160.6, 178.6. MS (ESI, Ion Trap): 474 [M + H]+, MS/MS 474, m/z (%): 346 (18), 322 (100), 168 (4). Anal. Calcd for C21H28BN5O5S: C, 53,28; H, 5,96; N, 14,80, S, 6,77. Found: C, 53.01; H, 6.10; N, 14.66; S, 6.55.

(+)-Pinanediol (1R)-2-[4-cyano-[1,2,3]triazol-1-yl]-1-(2-thienylacetylamino)ethaneboronate (2f). Propiolonitrile was prepared according to literature procedure.17 The reaction was terminated after 2 hrs. The crude residue triturated from Et2O to afford 2f as a beige solid (174 mg, 99% yield), mp 73 °C (dec). [α]D – 60.0 (c 1.0, MeOH). 1H NMR (400 MHz, MeOD): δ 0.90 (3H, s, pinanyl CH3), 1.31 (3H, s, pinanyl CH3), 1.38 (3H, s, pinanyl CH3), 1.43 (1H, d, J = 10.4, pinanyl Hendo), 1.79-2.40 (5H, m, pinanyl protons), 3.19 (1H, dd, J = 3.9, 10.2, BCHCH2), 3.97 (2H, s, CH2CONH), 4.22 (1H, d, J = 6.8, CHOB), 4.47 (1H, dd, J = 10.2, 14.6, BCHCH2),


29


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 30 of 43

4.62 (1H, dd, J = 3.9, 14.6, BCHCH2), 6.98-7.00 (2H, m, Har), 7.35 (1H, d, J = 4.8, Har), 8.73 (1H, s, CHtriazole). 13C NMR (100 MHz, MeOD): δ 22.3, 26.2, 26.4, 28.3, 31.0, 36.3, 37.8, 40.0, 44.0 (br, CB), 52.2, 52.7, 76.2, 83.3, 111.4, 120.2, 125.4, 126.7, 127.3, 131.3 (CHtriazole), 133.1, 177.3. MS (ESI, Ion Trap): 440 [M + H]+, MS/MS 440, m/z (%): 346 (26), 288 (100), 212 (8), 194 (6), 150 (5). Anal. Calcd for C21H26BN5O3S: C, 57.41; H, 5.96; N, 15.94, S, 7.30. Found: C, 57.45; H, 6.11; N, 15.79; S, 7.08. (+)-Pinanediol

(1R)-2-[4-(3-cyanophenyl)-[1,2,3]triazol-1-yl]-1-(2-

thienylacetylamino)ethaneboronate (2g). 3-Ethynylbenzonitrile was prepared according to literature procedure.18 The reaction was terminated after 2 hrs. The crude residue triturated from Et2O to afford 2g as a beige solid (148 mg, 72% yield), mp 78 °C (dec). [α]D – 64.8 (c 1.2, CHCl3). 1H NMR (400 MHz, CDCl3): δ 0.87 (3H, s, pinanyl CH3), 1.29 (3H, s, pinanyl CH3), 1.41 (1H, d, J = 13.6, pinanyl Hendo),1.42 (3H, s, pinanyl CH3), 1.82-2.40 (5H, m, pinanyl protons), 3.32 (1H, b, BCHCH2), 3.91 (2H, s, CH2CONH), 4.30 (1H, d, J = 7.5, CHOB), 4.504.60 (2H, m, BCHCH2), 6.94-6.98 (2H, m, Har), 7.23 (1H, d, J = 5.0, Har), 7.26 (1H ,b, NHCO), 7.52-7.61 (3H, m, Har), 7.85 (1H, s, Har), 8.01 (1H, s, CHtriazole). 13C NMR (100 MHz, CDCl3): δ 24.3, 26.8, 27.4, 29.1, 34.0, 36.6, 38.4, 40.1, 42.3 (br, CB), 52.2, 52.5, 77.3, 84.8, 113.3, 118.6 (CHtriazole), 126.4, 127.8, 128.3, 129.2, 129.87, 129.90, 131.6, 131.9, 133.1, 175. HRMS (ESITOF) m/z: [M+H]+ Calcd for C27H30BN5O3S: 516,2235; Found: 516,2254. Anal. Calcd for C27H30BN5O3S: C, 62.92; H, 5.87; N, 13.59, S, 6.22. Found: C, 63.05; H, 5.70; N, 13.49; S, 6.00.

General procedure for tetrazole formation:


30

Page 31 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


In a microwave glass vial the cyano derivatives 2f and 2g (0.4 mmol) and tetrabutylammonium fluoride trihydrate (0.4) were dissolved in trimethylsililazide (6.0 mmol) under Argon. The vessel was sealed and heated under microwave irradiation at 110 °C for 30 min. The reaction mixture was diluted with EtOAc (30 mL) and washed with HCl (1N, 3 x 10 mL), dried over Na2SO4, and concentrated under vacuum to afford the crude product which was thereafter purified as described.

(+)-Pinanediol

(1R)-2-[4-(2H-tetrazol-5-yl)-[1,2,3]triazol-1-yl]-1-(2-

thienylacetylamino)ethaneboronate (2h). The crude residue was triturated from Et2O to afford 2h as a beige solid (153 mg, 79% yield), mp 165-168 °C (dec). [α]D – 80.2 (c 1.1, MeOH). 1H NMR (400 MHz, MeOH): δ 0.88 (3H, s, pinanyl CH3), 1.29 (3H, s, pinanyl CH3), 1.37 (3H, s, pinanyl CH3), 1.43 (1H, d, J = 10.4, pinanyl Hendo),1.78-2.38 (5H, m, pinanyl protons), 3.24 (1H, dd, J = 4.2, 10.2, BCHCH2), 3.96 (2H, s, CH2CONH), 4.22 (1H, dd, J = 2.1, 8.8, CHOB), 4.50 (1H, dd, J = 10.2, 14.5, BCHCH2), 4.67 (1H, dd, J = 4.2, 14.5, BCHCH2), 6.91-6.98 (2H, m, Har), 7.28 (1H, dd, J = 1.2, 5.2, Har), 8.71 (1H, s, CHtriazole). 13C NMR (100 MHz, CDCl3): δ 24.5, 27.6, 27.8, 29.7, 32.4, 37.7, 39.2, 41.4, 45.8 (br, CB), 53.6, 53.8, 77.5, 84.6, 126.6 (CHtriazole), 126.7, 128.0, 128.6, 134.5, 134.9, 150.54, 178.7. HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C21H28BN8O3S: 483,2097; Found: 483,2097. Anal. Calcd for C21H27BN8O3S: C, 52.29; H, 5.64; N, 23.23, S, 6.65. Found: C, 52.10; H, 5.55; N, 23.18; S, 6.59.

(+)-Pinanediol

(1R)-2-[4-(3-(2H-tetrazol-5-yl)phenyl)-[1,2,3]triazol-1-yl]-1-(2-

thienylacetylamino)ethaneboronate (2j). The crude residue was triturated from Et2O to afford


31


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 32 of 43

2j as a beige solid (205 mg, 92% yield), mp 140-142 °C (dec). [α]D – 70.3 (c 1.3, MeOH). 1H NMR (400 MHz, MeOH): δ 0.88 (3H, s, pinanyl CH3), 1.28 (3H, s, pinanyl CH3), 1.38 (3H, s, pinanyl CH3), 1.43 (1H, d, J = 10.3, pinanyl Hendo),1.78-2.38 (5H, m, pinanyl protons), 3.26 (1H, dd, J = 4.1, 10.5, BCHCH2), 3.98 (2H, s, CH2CONH), 4.22 (1H, dd, J = 2.1, 8.5, CHOB), 4.57 (1H, dd, J = 10.5, 14.5, BCHCH2), 4.60 (1H, dd, J = 4.1, 14.5, BCHCH2), 6.94 (1H, dd, J = 3.4, 5.2, Har), 6.99 (1H, dd, J = 1.1, 3.4, Har), 7.30 (1H, dd, J = 1.1, 5.2, Har), 7.64 (1H, t, J = 7.9, Har), 7.98 (1H, dt, J = 1.4, 7.9, Har), 8.46 (1H, s, CHtriazole and Har).

13

C NMR (100 MHz,

CDCl3): δ 24.5, 27.6, 27.8, 29.7, 32.5, 37.7, 39.1, 41.4, 45.7 (br, CB), 53.6, 53.7, 77.5, 84.6, 123.3, 125.2, 126.4 (CHtriazole), 126.8, 127.7, 128.0, 128.7, 129.4, 131.1, 133.3, 134.6, 147.6, 157.7, 178.6. HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C27H32BN8O3S: 559,2411; Found: 559,2433. Anal. Calcd for C27H31BN8O3S: C, 58.07; H, 5.60; N, 20.06, S, 5.74. Found: C, 57.81; H, 5.66; N, 19.89; S, 5.70. General Procedure for pinanediol removal. The pinanediol esters 2b-e, and 2h-j (0.2 mmol) were dissolved in CH3CN (3 mL) and HCl (0.6 mmol of a 1M solution in degassed H2O), phenylboronic acid (isobutylboronic acid in case of 3h and 3j) (0.18 mmol) and n-hexane (2 mL) were sequentially added and the resulting biphasic solution was vigorously stirred. After 20 min the n-hexane solution (containing the pinanediol phenylboronate or isobutylboronate) was removed and fresh n-hexane (3 mL) added. This last procedure was repeated several times until a TLC analysis of the n-hexane layer not revealed anymore phenylboronate or isobutylboronate production (total reaction time 3 hours). The acetonitrile phase was concentrated, and the crude purified as reported, affording the desired compounds 3b-e and 3h-j. Copper (II) concentration in these products was found below 0.5 ppm through plasma analysis on a ICP-MS instrument.


32

Page 33 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


The enantiomeric purity of chiral boronic acids was checked by reconversion into their pinanediol esters. In particular, final compounds 3b, 3d-e and 3h-j were allowed to react with an equimolar amount of (+)-pinanediol in anhydrous THF: the NMR spectra of the crude products displayed the presence of a single diastereoisomer, proving that no racemization occurred during transesterification.

(1R)-2-(4-carboxymethyl-[1,2,3]triazol-1-yl)-(2-thienylacetylamino)ethaneboronic acid (3b). The crude residue was triturated from Et2O to afford 3b as beige solid (62 mg, 92% yield), mp 84°C (dec). [α]D = –75.0 (c 1.0, MeOH). 1H NMR (400 MHz, MeOD): δ 3.25 (1H, dd, J = 4.5, 9.7, BCH), 4.03 (4H, s, CH2CO and CH2COOH), 4.52 (1H, dd, J = 9.7, 14.4, BCHCH2), 4.66 (1H, dd, J = 4.5, 14.4, BCHCH2), 6.99 (1H, dd, J 3.5, 5.0, Har), 7.03-7.15 (1H, m, Har), 7.36 (1H, dd, J = 1.4, 5.0, Har), 8.47 (1H, s, CHtriaz).

13

C NMR (100 MHz, MeOD): δ

30.2, 32.3, 46.3 (br, CB, not seen), 56.2, 127.0, 128.2, 129.0, 134.5 (CHtriazole), 170.1, 179.4. MS (ESI, Ion Trap): 339 [M + H]+, MS/MS 339, m/z (%): EI-MS and elemental analysis results were not obtainable,24 but exposure of 3b to an equimolar amount of (+)-pinanediol in anhydrous THF afforded compound 2b in quantitative yield and satisfactory elemental analysis results. Anal. Calcd for C22H29BN4O5S: C, 55,94; H, 6,19; N, 11,86; S, 6, 79. Found: C, 56.18; H, 6.33; N, 11.68; S, 6.60.

(1R)-2-(4-carboxamido-[1,2,3]triazol-1-yl)-1-(2-thienylacetylamino)ethaneboronate (3d) The crude residue was triturated from Et2O to afford 3d as beige solid (62 mg, 96% yield), mp 90-92°C. [α]D = –107.9 (c 0.8, MeOH). 1H NMR (400 MHz, MeOD): δ 3.21 (1H, dd, J = 3.8,


33


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 34 of 43

10.2, BCH), 4.02 (2H, s, CH2CO), 4.22 (1H, dd, J = 10.2, 14.4, BCHCH2), 4.55 (1H, dd, J = 3.8, 14.4, BCHCH2), 6.99-7.04 (2H, m, Har), 7.34-7.37 (1H, m, Har), 8.46 (1H, s, CHtriaz). 13C NMR (100 MHz, MeOD): δ 13C NMR (101 MHz, CDCl3) δ 32.0, 47.2 (br, CB), 53.7, 126.8, 128.1, 128.2, 128.5, 128.3, 131.0, 134.5, 134.7, 179.1. EI-MS and elemental analysis results were not obtainable,24 but exposure of 3d to an equimolar amount of (+)-pinanediol in anhydrous THF afforded compound 2d in quantitative yield and satisfactory elemental analysis results. Anal. Calcd for C21H28BN5O4S: C, 55.15; H, 6.17; N, 15.31, S, 7.01. Found: C, 55.36; H, 6.10; N, 15.09; S, 6.84.

(1R)-2-(4-idroxycarbamoyl-[1,2,3]triazol-1-yl)-1-(2thienylacetylamino)ethaneboronic acid (3e). The crude residue was triturated from Et2O to afford 3e as beige solid (62 mg, 91% yield), mp 241-243 °C. [α]D = –80.9 (c 0.9, MeOH). 1H NMR (400 MHz, MeOD): δ 3.19 (1H, dd, J = 3.5, 10.2, BCH), 4.00 (2H, s, CH2CO), 4.41(1H, dd, J = 10.2, 14.2, BCHCH2), 4.52 (1H, dd, J = 3.5, 14.2, BCHCH2), 6.95-7.04 (2H, m, Har), 7.29-7.41 (1H, m, Har), 8.41 (1H, s, CHtriaz). 13C NMR (100 MHz, MeOD): δ 32.0, 47.3 (br, CB), 53.5, 126.9, 128.1, 128.5, 128.9, 134.4 (CHtriazole), 134.7, 179.3 EI-MS and elemental analysis results were not obtainable,24 but exposure of 3e to an equimolar amount of (+)-pinanediol in anhydrous THF afforded compound 2e in quantitative yield and satisfactory elemental analysis results. Anal. Calcd for C21H28BN5O5S: C, 53,28; H, 5,96; N, 14,80, S, 6,77. Found: C, 52.90; H, 6.17; N, 14.96; S, 6.60.


34

Page 35 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(1R)-2-[4-(2H-tetrazol-5-yl)-[1,2,3]triazol-1-yl]-1-(2thienylacetylamino)ethaneboronic acid (3h). The crude residue was triturated from acetonitrile to afford 3h as yellowish solid (56 mg, 81% yield), mp 221°C. [α]D = –96.5 (c 0.5, MeOH). 1H NMR (400 MHz, MeOD): δ 3.25 (1H, dd, J = 4.8, 10.1 BCH), 4.00 (2H, s, CH2CO), 4.48 (1H, dd, J = 10.1, 14.5, BCHCH2), 4.61 (1H, dd, J = 4.2, 14.5, BCHCH2), 6.96 (1H, dd, J = 3.5, 5.1, Har), 7.01 (1H, dd, J = 1.3, 3.5, Har), 7.31 (1H, dd, J = 1.3, 5.1, Har), 8.66 (1H, s, CHtriaz).

13

C

NMR (100 MHz, MeOD): δ 32.1, 47.2 (br, CB), 53.7, 126.5 (CHtriazole), 126.8, 128.1, 128.8, 134.5, 134.9, 150.6, 179.2. EI-MS and elemental analysis results were not obtainable,24 but exposure of 3h to an equimolar amount of (+)-pinanediol in anhydrous THF afforded compound 2h in quantitative yield and satisfactory elemental analysis results. Anal. Calcd for C21H27BN8O3S: C, 52.29; H, 5.64; N, 23.23; S, 6.65. Found: C, 52.07; H, 5.59; N, 23.18; S, 6.57. (1R)-2-[4-(3-(2H-tetrazol-5-yl)phenyl)-[1,2,3]triazol-1-yl]-1-(2thienylacetylamino)ethaneboronate (3j). The crude residue was triturated from acetonitrile to afford 3j as beige solid (81 mg, 96% yield), mp 189-191 °C. [α]D = –81.9 (c 0.4, MeOH). 1H NMR (400 MHz, MeOD): δ 3.28 (1H, d, J = 4.0 BCH signal under MeOH), 4.03 (2H, s, CH2CO), 4.49 (1H, dd, J = 10.5, 14.5, BCHCH2), 4.62 (1H, dd, J = 4.0, 14.5, BCHCH2), 6.97 (1H, dd, J = 3.5, 5.3, Har), 7.03 (1H, dd, J = 1.2, 3.5, Har), 7.33 (1H, dd, J = 1.2, 5.3, Har), 7.71 (1H, dt, J = 0.4, 2.0, Har), 8.02-8.07 (2H, m, Har), 8.52 (1H, dt, 0.4, 1.7, Har), 8.63 (1H, s, CHtriaz). 13

C NMR (100 MHz, MeOD): δ 32.1, 47.0 (br, CB), 54.8, 124.8(CHtriazole), 125.6, 126.88,

126.92, 128.2, 128.7, 128.9, 129.8, 130.9, 131.4, 134.5, 146.3, 157.8, 179.3. EI-MS and elemental analysis results were not obtainable,31 but exposure of 3j to an equimolar amount of (+)-pinanediol in anhydrous THF afforded compound 2j in quantitative yield and satisfactory


35


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 36 of 43

elemental analysis results. Anal. Calcd for C27H31BN8O3S: C, 58.07; H, 5.60; N, 20.06; S, 5.74. Found: C, 57.83; H, 5.73; N, 19.99; S, 5.64.

Supporting Information Available: 1HNMR and 13CNMR spectra of compounds 3b, 3d-e and 3h-j. This material is available free of charge via the Internet at http://pubs.acs.org. ABBREVIATIONS ADC, Acinetobacter Derived Cephalosporinases; BATSIs, Boronic Acids Transition State Inhibitors; CuAAC, Copper-Catalyzed Azide-Alkyne Cycloaddition; BL, β-Lactamase; BLIs, β-Lactamase Inhibitors; MICs, Minimum Inhibitory Concentration; SAR, Structure activity Relationship; HSQC, Heteronuclear Single Quantum Coherence spectroscopy; HMBC, Heteronuclear Multiple Bond Correlation; NCF, nitrocefin; CAZ, Ceftazidime; SUL, sulbactam; THF,

tetrahydrofuran;

LC/MS,

Liquid

Chromatography/Mass

Spectrometry;

DMSO,

dimethylsulfoxyde; ESI, Electrospray Ionization; MeOH, methanol.

AUTHOR INFORMATION Corresponding authors: Fabio Prati, Ph.D.; e-mail: [email protected] Phone: +39059-2058570; Robert A. Bonomo, M.D.; e-mail: [email protected] Phone: 216-791-3800 ext 4645 Author contributions: EC, CR, FF and FP synthesized all of the BATSI compounds. MAT and RAB performed microbiological assays and kinetics. RAP, BJW, AAB, HCS, KAS, performed kinetics and determined all of the crystal structures.

All authors have contributed to the

manuscript and have given approval to the final version of the manuscript.


36

Page 37 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


ACKNOWLEDGMENT This work was supported by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program award number 1I01BX001974, and the Geriatric Research Education and Clinical Center VISN 10 supported RAB. This work was also supported by funds from: National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI063517 and R01AI100560. RAB, FP and EC also received support from the Harrington Foundation. As a Student Summer Scholar (Marybeth Koeze Fellow) in the Office of Undergraduate Research and Scholarship at GVSU, H.S. was supported to carry out this work. Additionally, A.B. was supported by the McNair Scholars Program at GVSU. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs.

REFERENCES 1. Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., Spellberg, B. (2017) Clinical and Pathophysiological Overview of Acinetobacter Infections: A Century of Challenges. Clin. Microb. Rev., 30(1), 409-447. DOI: 10.1128/CMR.00058-16 2.

Bonomo, R. A., Szabo, D. (2006) Mechanism of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect. Dis. 43 (Suppl 2), 549-56.


37


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

3.

Page 38 of 43

Drawz, S. M., Papp-Wallace, K. M., Bonomo, R. A. (2014) New β-lactamase inhibitors: a therapeutic renaissance in a MDR world. Antim. Agents Chemother, 58, 1835-46. DOI: 10.1128/AAC.00826-13

4. Werner, J. P., Mitchell, J. M., Taracila, M. A., Bonomo, R. A., Powers, R. A. (2017) Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamase. Protein Sci. 26(3), 515-526. DOI:10.1002/pro.3100; 5. Brem, J., Cain, R., Cahill, S., McDonough, M. A., Clifton, I. J., Jiménez-Castellanos, J. C., Avison, M. B., Spencer, J., Fishwick, C. W., Schofield, C. J. (2016) Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat Commun. 7, 12406. DOI: 10.1038/ncomms12406; 6. Rojas, L. J., Taracila, M. A., Papp-Wallace, K. M., Bethel, C. R., Caselli, E., Romagnoli, C., Winkler, M. L., Spellberg, B., Prati, F., Bonomo, R. A. (2016) Boronic Acid Transition State Inhibitors Active against KPC and Other Class A β-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design. Antimicrob. Agents Chemother, 60(3), 1751-9. DOI: 10.1128/AAC.02641-15; 7. Powers, R. A., Swanson, H. C., Taracila, M. A., Florek, N. W., Romagnoli, C., Caselli, E., Prati, F., Bonomo, R. A., Wallar, B. J. (2014) Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of Acinetobacter baumannii. Biochemistry, 53(48), 7670-9. DOI: 10.1021/bi500887n. 8.

Drawz, S. M., Babic, M., Bethel, C.R., Taracila, M., Distler, A. M., Ori, C., Caselli, E., Prati, F., Bonomo, R. A. (2010) Inhibition of the class C beta-lactamase from


38

Page 39 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Acinetobacter spp.: insights into effective inhibitor design. Biochemistry, 49(2), 329-40. DOI: 10.1021/bi9015988. 9. Strynadka, N. C., Adachi, H., Jensen, S. E., Johns K., Sielecki, A., Betzel C., Sutoh K., James, M. N. (1992) Molecular structure of the acyl-enzyme intermediate in β-lactam hydrolysis at 1.7 Å resolution. Nature, 359, 700-705. DOI: 10.1038/359700a0 10. Zafaralla, G., Manavathu, E. K., Lerner, S.A., Mobashery, S. (1992) Elucidation of the role of Arginine-244 in the turnover processes of class A β-lactamases. Biochemistry, 31,3847–3852. 11. Marciano, D. C., Brown, N. G., Palzkill, T. (2009) Analysis of the plasticity of location of the Arg244 positive charge within the active site of the TEM-1 β-lactamase. Protein Sci. 18, 2080–2089. DOI: 10.1002/pro.220. 12. Caselli, E., Romagnoli, C., Vahabi, R., Taracila, M. A., Bonomo, R. A., Prati, F. (2015) Click Chemistry in Lead Optimization of Boronic Acids as β-Lactamase Inhibitors. J. Med. Chem. 58(14), 5445-58. DOI: 10.1021/acs.jmedchem.5b00341. 13. Morandi, F.; Caselli, E.; Morandi, S.; Focia, P. J.; Blazquez, J.; Prati, F.; Shoichet, B. K. Nanomolar Inhibitor of AmpC β-lactamase. (2003) J. Am. Chem. Soc. 125(3), 685-695. DOI: 10.1021/ja0288338 14. Drawz, S.M., Taracila, M., Caselli, E., Prati, F., Bonomo, R.A. (2011) Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase. Protein Science, 20(6), 941-58. DOI: 10.1002/pro.612.


39


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 40 of 43

15. Strubing, D., Neumann, H., Klaus, S., Hubner S., Beller, M. (2005) A facile and efficient synthesis of enyne-reaction precursors by multicomponent reaction. Tetrahedron, 61, 11333-11344. 16. Suzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., Tsumoto, H., Tatum, P. R., Mizukami, T., Nakagawa, H., Iida, S., Ueda, R., Shirahige, K. and Miyata N. (2012) Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries. J. Med. Chem. 55, 9562-9575. DOI: 10.1021/jm300837y 17. Jung, M. E., Buszek, K. R. (1988) The stereochemistry of addition of trialkylammonium and pyridinium tetrafluoroborate salts to activated acetylenes. Preparation of novel dienophiles for Diels-Alder reactions. J. Am. Chem. Soc. 110(12), 3965-9. 18. Bertrand, H. C., Schaap, M., Baird, L., Georgakopoulos, N. D., Fowkes, A., Thiollier, C., Kachi, H., Dinkova-Kostova, A. T., Wells, G. (2015) Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein Interaction. J. Med. Chem. 58(18), 7186-7194. DOI: 10.1021/acs.jmedchem.5b00602 19. Beesley, T., Gascoyne, N., Knott-Hunziker, V., Petursson, S., Waley, S. G., Jaurin, B. Grundstrom, T. (1983) The inhibition of class C β-lactamases by boronic acids. Biochem. J. 209, 229-233.


40

Page 41 of 43

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


20. Crompton, I.E., Cuthbert, B.K., Lowe, G., Waley, S.G. (1988) β-Lactamase inhibitors. The inhibition of serine β-lactamases by specific boronic acids. Biochem. J. 251, 453459. 21. Hecker, S. J., Reddy, K. R., Totrov, M., Hirst, G. C., Lomovskaya, O., Griffith, D. C., King, P., Tsivkovski, R., Sun, D., Sabet, M., Tarazi, Z., Clifton, M. C., Atkins, K., Raymond, A., Potts, K. T., Abendroth, J., Boyer, S. H., Loutit, J. S., Morgan E. E., Durso, S., Dudley, M. N. (2015) Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs Class A serine carbapenemases. J. Med. Chem., 58(9), 3682–3692. DOI: 10.1021/acs.jmedchem.5b00127 22. Lapuebla, A., Abdallah, M., Olafisoye, O., Cortes, C., Urban C., Quale J., Landman D. (2015) Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City. Antimicrob. Agents Chemother. 59(8),4856-60. DOI: 10.1128/AAC.00843-15. 23. Dougherty, D. A. (2013) The cation-pi interaction. Acc. Chem. Res. 46(4), 885-893. DOI: 10.1021/ar300265y. 24. Lavanya, P., Ramaiah, S. & Anbarasu, A. (2013) Cation–π Interactions in β-Lactamases: The Role in Structural Stability. Cell Biochem. Biophys. 66, 147. DOI: 10.1007/s12013012-9463-x. 25. Kabsch, W. (2010) Xds. Acta Crystallogr. D Biol. Crystallog. 66, 125-132. DOI: 10.1107/S0907444909047337


41


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 42 of 43

26. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software, J. Appl. Crystallogr. 40, 658-674. DOI: 10.1107/S0021889807021206 27. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular-structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255. DOI: 10.1107/S0907444996012255 28. CCP4 (Collaborative Computational Project Number 4). (1994) The CCP4 suite: programs for protein crystallography, Acta Crystallogr. Section D, 50, 760-763. DOI:10.1107/S0907444994003112. 29. Emsley, P., and Cowtan, K. (2004) Coot: Model-building tools for molecular graphics, Acta Crystallogr. Section D. 60, 2126-2132. 30. Clinical and Laboratory Standards Institute. (2017) Performance Standards for antimicrobial Susceptibility Testing; Seventeenth Informational Supplement, Vol. 27 31. Hall, D., G. In Boronic Acids, 2nd ed.; Hall, D., G.; Wiley-VCH Verlag & Co: Germany, 2011, Vol 1, pp 76-77. For Table of Contents Use Only


42

Page 43 of 43


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ACS Paragon Plus Environment

43

Inhibition of Acinetobacter-Derived Cephalosporinase: Exploring the

Recommend Documents